has been demonstrated in the heart of various species. However, its presence in human heart is still debated. In the literature, high to undetectable levels have been reported. We studied the arterial-venous mate difference across the heart of patients undergoing both routine cardiac catheterization and percutaneous transluminal coronary angioplasty.
Urate is the end product of the reaction catalysed by xanthine oxidoreductase. In 10 patients, studied before angioplasty, the plasma mate level in the great cardiac vein exceeded the arterial one by 26 + 10 nmol/ml (P = 0.028). In a further 13 patients, urate production was maximal immediately after the last of four consecutive occlusions (23 If: 8 nmol/ml, P = 0.018) and concomitant with increased coronary sinus hypoxanthine levels. We conclude that xanthine oxidoreductase is probably present in the heart of patients, suffering from ischemic heart disease, and responsible for the increase in mate production during transient myocardial ischemia.
Introduction
Xanthine oxidoreductase activity has been demonstrated in the myocardium of a number of species (see Schoutsen and De Jong, 1987) . Limited data are available on the enzyme in human heart. Autopsy material indicates high xanthine oxidase activity (Krenitsky et al., 1974; Wajner and Harkness, 1988) . Histochemical techniques have shown large amounts of the enzyme in human heart endothelium (Jarasch et al., 1986) . On the other hand, several authors have reported very low to undetectable xanthine oxidoreductase activity in human heart (Ramboer, 1969; Eddy et al., 1987; Muxfeldt and Schaper, 1987) Preliminary observations assessing cardiac urate production in patients during pacing stress test at the University of Alabama ~Nelson et al., 1977) and in patients during coronary angiography in the National Institute of Cardiology, Warsaw (Czarnecki, 1988) have suggested that the human heart may be capable of urate production. We present evidence which shows that the human heart can produce significant amounts of urate. This observation suggests that a cardiac xanthine oxidoreductase is active in patients with ischemic heart disease. were assayed retrospectively (Group 1). Subsequently, in a prospective study (Group 2, 13 patients), urate and hypoxanthine concentrations were measured in arterial and coronary sinus plasma before, during and after angioplasty. In both studies, arterial blood was taken from the femoral artery. Great cardiac vein blood was sampled via the distal opening of a Webster flow catheter (Group 1) and coronary sinus blood via a diagnostic catheter (Group 2). All patients had a proximal stenosis < 1 cm from the origin of the left anterior descending artery and no collateral filling to the region supplied by the artery, seen at angiography. Amipaque or Isopaque contrast agents (Nyegaard, Oslo, Norway) were used for angiography. In all patients, vasoactive substances, except short-lasting nitrates, were discontinued at least 12 h before the study.
Methods

Patients
The clinical characteristics are listed in Table 1 .
Assays
To prepare plasma, blood was mixed in a heparinized tube with an equal volume of icecold 154 mM NaCl, containing 20 PM dipyridamole (Boehringer, Ingelheim, GFR) and 10 PM erythro-9-(2-hydroxy-3-nonyl) adenine (Wellcome, London, UK). These drugs were used to inhibit adenosine uptake and breakdown (Ontyd and Schrader, 1984; Edlund et al., 1985) . The plasma was kept at -80°C. Deproteinization was carried out with an equal volume of 8% HC104 (w/v) and the supernatant fraction neutralized with 2 M KOH/l M K,CO, . HPLC-determination of urate and hypoxanthine concentrations in the plasma extract were performed on a PBondapak CIS column. A 100 ~1 sample was eluted with a mixture of CH30H (100 ml) and KH,P04 (10 g/l, 1000 ml), pH 5-7, at a flow ART  CS  ART  CS  ART  CS  ART  CS  ART  CS  ART  CS   I  217  211  214  217  211  217  218  216  212  217  215  'IR  2  236  216  224  184  216  195  213  207  213  200  202  196  3  224  229  223  220  218  215  218  219  217  217  215  '211  4  279  291  280  290  279  281  236  292  245  284  262  "82  5  242  254  231  266  239  257  244  260  200  266  230  253  6  216  224  219  221  208  216  211  218  209  216  202 Bland and Altman (1986) .
Results
In the preliminary studies, mentioned in the Introduction, hearts produced urate. In the American study, the arterial and venous blood urate levels were 59 + 20 and 120 & 23 nmol/ml, resp. (n = 7, P = 0.003). In the Polish study, these values were 96 + 15 and 145 + 25 nmol/ml resp. (rz = 6, P = 0.028).
In Group 1, all patients had an isolated proximal left anterior descending artery stenosis and angina pectoris. In this group the arterial urate concentration was significantly lower than the coronary venous one (2 16 & 17 and 242 + 17 nmol/ml) ; a difference of 26 nmol/ml (P = 0.028). In seven out of 10 patients, the heart produced urate.
In a comparable patient population (Group 2, see Table 2 ), plasma urate concentrations were similar to those of Group 1, but the arterio-venous difference before coronary angioplasty was relatively small. Consequently we were unable to demonstrate significant urate production before coronary angioplasty. Analysis of data showed a significant increase in urate production during balloon inflations (F = 2.85; P < 0.05). After the third and fourth inflations, venous urate levels were significantly higher than arterial ones (Fig. 2) . They differed 14 nmol/ml (P = 0.009) and 23 nmol/ml (P = 0.018), resp. Even after 15 min of recovery, urate production was still significant.
The difference was 7 nmol/ml (P = 0.033).
In the latter study we also measured the arterial and coronary sinus hypoxanthine levels with HPLC. The arterial hypoxanthine T. Huizer et al.
-I -IO' I pre I 2 3 4 post Dilation FIGURE 2. Urate production by the heart of 13 patients with single left anterior descending coronary artery stenosis, before coronary angioplasty (pm), after each balloon deflation (dilation one to four) and after 15 min of recovery (post). Mean coronary venous-arterial values are given with 1 S.E.M. Significant urate production was found immediately after the last two dilations, and during recovery. plasma concentration slightly exceeded the venous one before angioplasty (0.58 & 0.07 and 0.42 + 0.07 nmol/ml, respectively, P = 0.015). Immediately following PTCA these values were 0.32 + 0.06 and 1.28 + 0.19 nmol/ml, respectively, P < 0.001 (average of four attempts). Thus cardiac uptake turned into production. Fifteen minutes after angioplasty arterial plasma hypoxanthine levels were not different from the venous ones.
Discussion
Xanthine oxidoreductase activity is detectable in the heart of a number of species (for reviews, see Schoutsen and De Jong, 1987 ; Downey et al., 1988) . In pig heart it seems to be absent (Podzuweit et al., 1986; Muxfeldt and Schaper, 1987) . In rabbit heart both Schoutsen et al. (1983) and Chambers et al. (1985) were unable to demonstrate the enzyme, but Wajner and Harness ( 1988) measured high activity. The literature on xanthine oxidoreductase in human heart is also conflicting. The reports vary from high (Krenitsky et al., 1974; Jarasch et al., 1986; Wajner and Harness, 1988) to (very) low levels (Watts et al., 1965; Ramboer, 1969; Eddy et al., 1987; Muxfeldt and Schaper, 1987) . We want to emphasize that in these reports the number of samples assayed was often very small. Muxfeldt and Schaper 119871 found verv low amounts of xanthine oxidoreductase in the two human heart biopsies studied. Krenitsky et al. (1974) reported data on one autopsy sample. These authors observed enzyme activity with ferricyanide as the electron acceptor but did not use NAD or oxygen as the cosubstrate. Allopurinol inhibited the activity. Eddy et al. (1987) could not demonstrate xanthine oxidoreductase in human ventricular tissue. Supposedly the four biopsies studied were not taken from ischemic hearts.
A possible explanation for the discrepancies in activity found could be a difference in quality of the hearts examined. Our data indicate that the enzyme could be active in the human heart in viva. We cannot exclude that the urate production measured originated from xanthine oxidoreductase activity in polymorphonuclear neutrophils, adhering to areas of the coronary endothelium that are injured by the balloon during inflation.
In the American and Polish studies, mentioned before, blood was deproteinized with HC104 which causes a partial loss during sample clean-up. Never the less the arteriovenous differences in urate were significant. Moreover, they suggested that patients with a more severe ischemic heart disease produced the highest amounts of urate. In the American study, patients experiencing pain during a pacing stress test released lactate and showed the highest urate production. Czarnecki (1988) observed that patients with a history of subendocardial infarction produced high amounts of urate whereas patients with normal myocardium or extensive myocardial damage produced less. Our present results support this idea. Group 1, which comprised patients with CCS grades III and IV, showed significant urate production before PTCA.
Group 2, in which four out of 13 patients were CCS grade II, only started to produce significant amounts of urate after several dilations. (Table  1) . It is likelv that this urate production was partly due to endothelial damage, caused by insertion of the guide wire and the balloon catheter. In Group 2 urate production, which was not significant before PTCA, became obvious after repetitive angioplasty attempts (Fig. 2) . Presumably, this is due to cardiac ATP breakdown, with a concomitant rise in hypoxanthine as a result of myocardial ischemia due to coronary occlusion by balloon inflation (sre also Serruys et al., 1989) . Hypoxanthine serves as a substrate for xanthine oxidoreductase. We suggest that the human heart ma) contain active xanthine oxidoreductase.
